Doxorubicin 13CD3 TFA salt

Doxorubicin 13CD3 TFA salt is a stable isotope labeled form of doxorubicin, a potent chemotherapy drug used in the treatment of various types of cancers, including breast cancer, bladder cancer, and lung cancer. This salt is composed of the stable isotope carbon-13, which replaces the unstable carbon-12 in the structure of doxorubicin. This labeling technique allows for the tracking of the drug in biological systems using mass spectrometry, which is useful for pharmacokinetic studies. Doxorubicin 13CD3 TFA salt works by inhibiting the growth and replication of cancer cells by intercalating into the DNA double helix and disrupting its structure. This leads to the inhibition of DNA and RNA synthesis and ultimately results in the death of cancer cells. The TFA salt form of doxorubicin is particularly useful for chemical synthesis and purification due to its solubility properties. However, it is important to note that doxorubicin can cause serious side effects, such as cardiotoxicity and immunosuppression, and its usage should be closely monitored by a healthcare professional. Additionally, the stable isotope labeling of doxorubicin 13CD3 TFA salt can increase the cost of production, making it less accessible for certain research applications. In conclusion, doxorubicin 13CD3 TFA salt is a valuable tool in the field of cancer research and drug development, with its stable isotope labeling providing important insights into its pharmacokinetics. However, its usage should be approached with caution due to its potential side effects and higher cost.